secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001193125-22-276404
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA reports Q3 2022 net loss $4.2M; receives first VABYSMO royalty from Roche
------------------------------------------------------------------------------

- Total revenues $0.5M, down from $0.9M in Q3 2021; milestone revenue in prior year period.
- Net loss $4.2M vs $4.4M year ago; cash $78.3M with no debt.
- First commercial payment received from Roche for VABYSMO (faricimab) in wAMD and DME: $0.5M.
- Received $2.5M milestone from Kuros after Regeneron's acquisition of Checkmate.
- Paid $3.0M milestone to Affitech triggered by EU approval of VABYSMO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312522276404/0001193125-22-276404-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312522276404/d347911d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-276404

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer